TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signaling
Liver fibrosis is a strong predictor of clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Fibrosis is a consequence of persistent liver cell injury and inflammation in which Toll-like receptors (TLRs) play a key initiating role. Here, we test the hypothesis that TLR5 is involved in the development of MASH and fibrosis using a combination of clinical data from multiple independent patient cohorts, single-cell liver transcriptomics, and human in vitro and ex vivo models. Hepatic TLR5 expression, but not TLR2 or TLR4, is associated with liver fibrosis and mortality. Plasma levels of TLR5's cognate ligand flagellin are increased in MASH with advanced fibrosis and fall with liver disease improvement. Mechanistically, we identify two parallel TLR5-mediated routes to hepatocyte injury: one elicited by flagellin and the other indirectly by lipid injury. Furthermore, hepatocyte TLR5 inhibition abrogates paracrine activation of hepatic stellate cells to suppress collagen production. This is also seen ex vivo in patient-derived precision-cut liver slices where TLR5 inhibition significantly reduces lipid-induced collagen deposition. These findings reveal a new role for TLR5 signaling, specifically in the development of advanced MASH fibrosis and may offer a novel disease-specific therapeutic approach.
Authors
- Charles A. Mein (ORCID: https://orcid.org/0000-0003-0811-9658)
- Raju Kumar (ORCID: https://orcid.org/0000-0001-7172-1671)
- Olivier Govaere (ORCID: https://orcid.org/0000-0002-4426-6930)
- Krista Rombouts (ORCID: https://orcid.org/0000-0001-9440-0571)
- Michèle Vacca (ORCID: https://orcid.org/0000-0002-1973-224X)
- Iris Ginés (ORCID: https://orcid.org/0000-0002-4549-9939)
- Gillian Hood (ORCID: https://orcid.org/0000-0003-3325-1140)
- Robert David Goldin (ORCID: https://orcid.org/0000-0001-5184-4519)
- Una Rose Wilcox (ORCID: https://orcid.org/0009-0008-1367-9864)
- Maria Castanho Martins (ORCID: https://orcid.org/0009-0007-8421-8814)
- Upkar S. Gill (ORCID: https://orcid.org/0000-0001-6146-9708)
- Tania Roskams (ORCID: https://orcid.org/0000-0002-2816-1530)
- William Alazawi (ORCID: https://orcid.org/0000-0002-3891-5914)
- John J. Loy (ORCID: https://orcid.org/0009-0001-6480-5436)
- James R. Boot (ORCID: https://orcid.org/0000-0002-5629-5026)
- Timothy James Kendall (ORCID: https://orcid.org/0000-0002-4174-2786)
- Neil Dufton (ORCID: https://orcid.org/0000-0002-6283-9210)
- Kalpana Devalia (ORCID: https://orcid.org/0009-0008-1885-7682)
- Maria Jiménez Ramos (ORCID: https://orcid.org/0009-0000-8273-0805)
- Jonathan Andrew Fallowfield (ORCID: https://orcid.org/0000-0002-5741-1471)
- James Hallimond Brindley (ORCID: https://orcid.org/0000-0002-7029-9891)
- Wenhao Li (ORCID: https://orcid.org/0000-0003-0717-9069)
- Ni Wang (ORCID: https://orcid.org/0000-0002-1796-7803)
- Seniye Anak (ORCID: https://orcid.org/0009-0009-6440-1851)
- Adam Goralcyzk (ORCID: https://orcid.org/0009-0002-9287-0953)
- Dania El Abyad (ORCID: https://orcid.org/0009-0004-2083-0236)
- Humza Malik
Institutions
- Queen Mary University of London (GB)
- King's College London (GB)
- The Royal Free Hospital (GB)
- Foundation for Liver Research (GB)
- Homerton University Hospital NHS Foundation Trust (GB)
- William Harvey Research Institute (GB)
- King's College Hospital (GB)
- Blizard Institute (GB)
- University College London (GB)
- Imperial College London (GB)
- University of Bari Aldo Moro (IT)
- University of Edinburgh (GB)
- KU Leuven (BE)
Publication Details
- Journal
- Science Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/sciadv.aef9541
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Barts Charity
- Academy of Medical Sciences
- Rosetrees Trust
- Guts UK
- Vlaamse regering
- Medical Research Council
- Innovate UK
- Medical Research Foundation
- Eurostars
- Eureka Therapeutics